Study of mRNA expression level and hypermethylation of CHFR promoter in the laryngeal squamous cell carcinoma tissue.
- Author:
Lixia HE
1
;
Wenyue JI
;
Jing YANG
;
Xudong ZHAO
Author Information
1. Department of Otolaryngology, the Shengjing Hospital of China Medical University, Shenyang, 110004, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Carcinoma, Squamous Cell;
genetics;
pathology;
Cell Cycle Proteins;
genetics;
CpG Islands;
DNA Methylation;
Female;
Gene Silencing;
Humans;
Laryngeal Neoplasms;
genetics;
pathology;
Male;
Middle Aged;
Neoplasm Proteins;
genetics;
Neoplasm Staging;
Poly-ADP-Ribose Binding Proteins;
Promoter Regions, Genetic;
RNA, Messenger;
genetics;
Ubiquitin-Protein Ligases
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2010;24(15):673-677
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relationship between the level of expression and hypermethylation of the CHFR gene and the occurrence and development of laryngeal squamous cell carcinoma (LSCC).
METHOD:The mRNA expression and promoter hypermethylation were detected by Realtime fluro-genetic quantitative PCR and methylation specific PCR in 50 LSCCs (LSCC group) and 15 normal laryngeal tissue (control group).
RESULT:1) CHFR mRNA was shown in the control group, while the mRNA was loss expression in the 2 LSCC (4%), and the level of mRNA expression was significantly lower in the LSCC group. The relative ratio was 0.50 +/- 0.12, which is 0.30 +/- 0.04 at the early stage of the LSCC and 0.70 +/- 0.21 at the advanced stage, respectively. The discrepancy had statistical significance (P<0.01). 2) The methylation rate of CHFR was 22% (11/50) in the LSCC tissues, which was not found in the normal tissues. The aberrant methylation of CHFR was observed in 10 of the patients at the stage I and stage II of LSCC , in 1 of the patients at the stage III, and was absent at the stage IV. There was significant difference between the aberrant methylation of CHFR and the stage of carcinoma (P<0.01). 3) The mRNA expression level of the aberrant methylation patients was 0.11 +/- 0.05, which was significantly lower than that of the unmethylation patients 0.75 +/- 0.13. Gene inactivation was observed in 2 of the 11 patients with the aberrant promoter methylation. The methylation was associated with the expression of mRNA, with the correlation coefficient 0.387 (P<0.05).
CONCLUSION:Hypermethylation of CHFR gene promoter is associated with loss or lower expression of CHFR mRNA in the LSCCs, and it may contribute to the occurrence and development of LSCC. The promoter aberrant methylation of CHFR may be one of the early diagnostic and therapeutic marker genes.
